Please ensure Javascript is enabled for purposes of website accessibility

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca

By Keith Speights - Nov 29, 2020 at 9:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.

Pfizer (PFE -0.76%) appears to be likely to be the first drugmaker, along with its partner BioNTech (BNTX 0.03%), to win U.S. emergency use authorization (EUA) for a coronavirus vaccine. AstraZeneca (AZN 0.20%), with plans to produce up to 3 billion doses next year, might distribute more doses of its COVID-19 vaccine globally than any other company.

Do these leading positions mean that Moderna (MRNA -0.11%) is playing second fiddle in the coronavirus vaccine race? Not for investors. Here are three key advantages that Moderna holds over both Pfizer and AstraZeneca.

Researcher in personal protective equipment holding a vaccine vial with another researcher in the background

Image source: Getty Images.

1. No sharing required

Many of us were taught in kindergarten that it's good to share -- and our kindergarten teachers were right. In the biopharmaceutical world, though, sharing profits can translate to slower growth. Both Pfizer and AstraZeneca will share the rewards gained from their COVID vaccines.

Pfizer, as mentioned earlier, teamed up with BioNTech on coronavirus vaccine candidate BNT162b2. The big drugmaker forked over $72 million in cash to its partner, and bought a $113 million stake in the German biotech. BioNTech is also eligible to receive milestone payments of up to $563 million. The two companies didn't reveal how they're splitting revenue and profits on any sales of BNT162b2, but Pfizer certainly won't pocket all of the money the vaccine could make.

AstraZeneca partnered with the University of Oxford to develop and distribute experimental COVID-19 vaccine AZD1222. No financial details of the collaboration were announced. However, you can bet that Oxford will receive some level of royalties from any sales of the vaccine.

Meanwhile, Moderna has full ownership of COVID-19 vaccine candidate mRNA-1273, and doesn't have to share any potential revenue or profits from sales of the vaccine. Granted, Arbutus Biopharma owns the patent to lipid nanoparticle (LNP) technology used in the past by Moderna. However, Moderna has publicly stated that mRNA-1273 doesn't use any technology covered by Arbutus' patent.

2. Platform possibilities

If AstraZeneca wins regulatory approvals for AZD1222, the company has no other vaccine candidates that use similar technology waiting in the wings. It's the same story for Pfizer. However, good news for Moderna's mRNA-1273 could bode well for the rest of the biotech's pipeline.

Moderna hopes to leverage commercial success for mRNA-1273 into a full-blown mRNA (messenger RNA) platform. In addition to mRNA-1273, the company's pipeline currently includes 12 other mRNA vaccines and therapies in clinical testing. Moderna thinks it could expand that number to as many as 50 clinical-stage programs if the anticipated big bucks from mRNA-1273 begin to pour in.

Believe it or not, Moderna CEO Stephane Bancel thinks that the biotech could even become the biggest vaccine company in the world within the next four years. That view could be overly optimistic, but Moderna should grow at a much faster rate than AstraZeneca or Pfizer because of its platform possibilities.

3. Size

Last -- and least, in a literal sense -- is Moderna's size advantage over Pfizer and AstraZeneca. You might be thinking, "What size advantage?" After all, Pfizer's market cap tops $200 billion. AstraZeneca's market cap is close to $140 billion. Moderna is tiny in comparison, with a market cap in the ballpark of $50 billion. However, Moderna's smaller size is actually a big advantage.

It's not surprising at all that Moderna's stock gains so far in 2020 have been a lot better than the performances turned in by AstraZeneca and Pfizer. That's because positive developments for mRNA-1273 have moved the needle a lot more for Moderna than similar positive developments for AZD1222 and BNT162b2 have done for AstraZeneca and Pfizer, respectively.

Moderna still has a lot more room to run than either AstraZeneca or Pfizer. An additional $5 billion to $10 billion annually would be nice for these two big drugmakers, but wouldn't cause either of the two pharma stocks to skyrocket. On the other hand, that kind of revenue would likely light a fire beneath Moderna's share price.

We should soon know if mRNA-1273 will win EUA in the U.S. and regulatory approvals in other countries. If it does, Moderna stands to make billions of dollars in a short period. Its size, combined with its full ownership of its COVID vaccine and its platform possibilities, will almost certainly make Moderna a much bigger winner again in 2021 than AstraZeneca and Pfizer.

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$170.96 (-0.11%) $0.18
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.40 (-0.76%) $0.38
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.02 (0.20%) $0.13
BioNTech SE Stock Quote
BioNTech SE
BNTX
$157.25 (0.03%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.